Next 10 |
home / stock / jnj / jnj articles
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70. RBC...
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday. The company posted adjusted EPS of $2.82, up 1...
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry ent...
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo...
The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contrac...
On Wednesday, Johnson & Johnson (NYSE: JNJ) reported its second quarter results that reflected a strong momentum of its medtech and innovative ...
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday. Following the market opening Wednes...
On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the ...
Sentiment will likely reverse course, with the index futures trading notably lower early Wednesday. The recent run-up ideally should render the moo...
News, Short Squeeze, Breakout and More Instantly...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 05:40:00 ET On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare c...